Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Mild cognitive impairment (MCI) is a syndrome which, depending on various neurobiological, psychological and social factors, carries a high risk of developing into dementia. As far as diagnostic uncertainty and the heterogeneous underlying pathophysiological mechanisms are concerned, only limited therapeutic options are currently available. Clinical trials involving a wide range of substances have failed to show efficacy on primary and secondary outcome parameters. Most results reflect not only a lack of effectiveness of drug therapy but also methodological constraints in true prodromal Alzheimer´s disease (AD) based on clinical criteria. Biomarkers may help to identify MCI as a prodromal phase of dementia, so it is important to use them to improve specificity of case selection in future studies. For MCI as a prodromal syndrome of AD, clinical trials with disease modifying drugs that target underlying pathological mechanisms such as amyloid-beta accumulation and neurofibrillary tangle formation may help develop effective treatment options in the future. Alternative pharmacological approaches are currently being evaluated in ongoing phase 1 and phase 2 studies. Nevertheless, a lack of approved pharmacotherapeutic options has led to specific interventions that focus on patient education and life-style related factors receiving increasing attention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“for clinical trials) implement such biomarkers as neuroimaging methods and cerebrospinal fluid evaluation and lead to four levels of diagnostic certainty [7] (see Table 1).”
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“cognitive stimulation), a few pharmacological treatment approaches exist that are mostly based on the assumption that MCI is a transitional pre-dementia stage of Alzheimer ́s Disease (AD) with positive biomarkers related to the pathophysiological mechanisms of AD [6].”
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 4×
“While in the Petersen study, the secondary preventive effect of donepezil on MCI was investigated, Salloway et al. [16] focused more on short-term symptomatic effects.”
InfluentialAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Amnestic MCI or prodromal Alzheimer's disease?
Dubois, B., & Albert, M. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00710-0 · Cited by 543
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 1×
“A sample of 1457 subjects with MCI participated, half of whom were given rofecoxib and the other half a placebo over a period of up to 4 years [26, 27].”
Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., & Irie, T. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09124-6 · Cited by 259 · cited 1×
“(AChE) activity demonstrated in PET studies [10] and the atrophy of the nucleus basalis of Meynert as revealed using structural MRI [11].”
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193 · cited 1×
“According to the Cochrane library, there is substantial evidence from RCTs that statins given late in life to individuals at risk of vascular disease do not prevent AD or dementia although biologically it seems feasible that statins could prevent dementia due to their role in cholesterol reduction [35].”
Possible therapeutic value of melatonin in mild cognitive impairment: A retrospective study
Furio, A. M., Brusco, L. I., & Cardinali, D. P. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00491.x · Cited by 167 · cited 1×
“These include intranasal insulin [37], melatonin [38], nicotine patches [39], Chinese plant extracts [40] and other antioxidants, various nutritional supplements (including vitamins and omega-3 fatty acids), ampakines, testosterone, metformin and levodopa.”
Cited by
Mild Cognitive Impairment in Clinical Practice: A Review Article
Jongsiriyanyong, S., & Limpawattana, P. (2018) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317518791401 · Cited by 457
Management of mild cognitive impairment (MCI): The need for national and international guidelines
Kasper, S., Bancher, C., Eckert, A., Förstl, H., Frölich, L., Hort, J., Korczyn, A. D., Kressig, R. W., Levin, O., & Palomo, M. S. M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1696473 · Cited by 233
Huckans, M., Hutson, L., Twamley, E., Jak, A., Kaye, J., & Storzbach, D. (2013) · Neuropsychology Review · doi:10.1007/s11065-013-9230-9 · Cited by 201
“…inhibitors such as donepezil, rivastigmine, and galantamine, Vitamin E, rofecoxib, piracetam, memantine) or are under current investigation , these are reviewed elsewhere (Jelic et al. 2006; Karakaya et al. 2013; Popp and Arlt 2011) and are beyond the scope of the present paper.”
BackgroundCicchese, J. J., & Berry, S. D. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00001 · Cited by 174
Yang, H., Leaver, A. M., Siddarth, P., Paholpak, P., Ercoli, L., St. Cyr, N. M., Eyre, H. A., Narr, K. L., Khalsa, D. S., & Lavretsky, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00277 · Cited by 61
“To date, preventive measures against cognitive decline have mainly focused on pharmacotherapy (Karakaya et al., 2013) and physical exercise (Smith et al., 2010; Behrman and Ebmeier, 2014).”
Background
Metadata
- Authors
- Karakaya, T., Fußer, F., Schroder, J., & Pantel, J.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 102-108
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2060458649
- Cited by
- 102
- References
- 14
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.